SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for the Non-Opioid Treatment of Pain
February 4, 2025Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
December 19, 2024SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-opioid Treatments for Pain
December 18, 2024Valora Therapeutics Raises $30 Million Seed Financing from Top Investors to Transform Immunotherapy with a Novel Glyco-immune Checkpoint Platform
November 20, 2024TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
November 13, 2024Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024
November 7, 2024- See All Press Releases
